CAMBRIDGE, Mass., April 12 /PRNewswire-FirstCall/ -- Javelin Pharmaceuticals, Inc. , a leading developer of innovative pain medications, today announced that David Bernstein, Esquire, has joined the company as General Counsel and Chief Intellectual Property Counsel. Mr. Bernstein will be a member of the senior management team and serve as Javelin’s primary corporate interface for all IP and corporate legal matters. In that capacity, he will be involved in all phases of U.S. and foreign patent preparation and prosecution.
Daniel Carr, M.D., Chief Executive Officer of Javelin commented, “David’s extensive experience in all aspects of IP counseling and litigation, combined with his strong domain expertise make him a great fit for Javelin. We have three pain products in late-stage clinical development, and one product nearing commercialization in Europe. David will play a key role in ensuring Javelin protects its intellectual property assets. We are thrilled to have further enhanced Javelin’s senior management team with an attorney of David’s stature.”
With more than twenty years of IP law experience in the U.S. and Europe, Mr. Bernstein has extensive experience working in the biopharmaceutical sector, including biotechnology, biomaterials, and medical devices. His experience further includes semiconductor and microfabrication technologies. He has an extensive background in obtaining and enforcing patents, trademarks and copyrights and intellectual property licensing.
Prior to joining Javelin, Mr. Bernstein was General Counsel and Chief Intellectual Property Counsel at U.S. Genomics, where he served on the senior management team. Prior to joining U.S. Genomics, Mr. Bernstein co-founded the Intellectual Property section at the Boston law firm Mintz, Levin, Cohn, Ferris, Glovsky & Popeo and served as the section’s Chairperson. Mr. Bernstein formerly served as Intellectual Property Counsel for 3M Company, and has been a partner at Wolf, Greenfield & Sacks, a firm specializing in intellectual property law. Mr. Bernstein is a graduate of Yale University and holds a law degree from Franklin Pierce Law Center.
About Javelin:
With corporate headquarters in Cambridge, MA, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market. For additional information, please visit the website at http://www.javelinpharmaceuticals.com.
Forward-looking Statement
Some of the statements included in this press release, particularly those anticipating future financial performance, clinical and business prospects for our lead drug candidates Dyloject(TM), Rylomine(TM) and PMI-150, growth and operating strategies and similar matters, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully complete cost-effective clinical trials for the drug candidates in our pipelines, including Dyloject(TM), Rylomine(TM) and PMI-150; we may not be able to meet anticipated development timelines for Dyloject(TM), Rylomine(TM) and PMI-150 due to recruitment, clinical trial results, manufacturing capabilities or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.javelinpharmaceuticals.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.
Javelin Pharmaceuticals, Inc.
CONTACT: June Gregg of Javelin Pharmaceuticals, Inc., +1-212-554-4550,jgregg@javelinpharmaceuticals.com; or Bryan P. Murphy of LaVoie Group,+1-781-596-0200, x105, bmurphy@lavoiegroup.com
Web site: http://www.javelinpharmaceuticals.com/
